Definium Therapeutics

We’re bringing Definium to NYC on April 22nd! At our Investor & Analyst Day in New York City on April 22, 2026, from 10:00 AM – 12:00 PM ET. Our executive leadership team, alongside leading external speakers, will share perspectives on the evolving treatment landscape in generalized anxiety disorder (GAD) and major depressive disorder (MDD), bringing both clinical insight and real-world context. We’ll highlight: + DT120 ODT (lysergide tartrate), our lead Phase 3 investigational program + Expectations for 2026 topline data readouts + The broader opportunity to advance care in anxiety and depression If you’re following innovation in psychiatry, this is one to watch. More details and registration: ir.definiumtx.com/news-events/pr… #InvestorRelations #MentalHealth #Neuroscience #CNS #HealthcareInnovation $DFTX

So proud to see our CEO, Robert Barrow, featured in a powerful article, sharing perspectives about creating lasting change in mental health treatment through rigorous science and collaboration. Read the full article here: bit.ly/4m7nB0z #MentalHealth

We will be joining a series of investor conversations this spring—sharing how we’re forging a new era of psychiatry. These events bring together investors, researchers, and industry leaders to explore how new approaches to treatment can address the underlying causes of psychiatric and neurological disorders. Read the full press release for details, access information, and webcast links: ir.definiumtx.com/news-events/pr…

After reporting strong full-year 2025 results, our CEO, Robert Barrow, reflects on the momentum behind Definium, from the January brand launch to the anticipation of three Phase 3 readouts ahead. The year ahead will be a defining one for Definium and for the future of psychiatry. linkedin.com/pulse/momentum… #Biotechnology #BrainHealth #MentalHealth #ClinicalTrials #Psychiatry #BiotechInnovation $DFTX

Our #ReroutingMinds campaign highlights pharmaceutical LSD's potential to address root causes of psychiatric distress. Read the full @endpts piece we sponsored: endpoints.news/sp/a-psychedel… #MentalHealthInnovation #DefiniumTheraputics #Neuroscience #BrainHealth #Sponsored

We published our full-year 2025 financial results and business updates today. A replay of this afternoon’s conference call is now available.   Read the full press release here: ir.definiumtx.com/news-events/pr… $DFTX

Over the coming weeks, our leadership team will be engaging directly with the investment community at several key conferences. We look forward to advancing the conversation around our progress and long-term vision. Read the press release for additional details: ir.definiumtx.com/news-events/pr… $DFTX

We will report our full year 2025 financial results and business updates during a live webcast at 4:30 p.m. EST on February 26, 2026. See press release here for details and to register: ir.definiumtx.com/news-events/pr… $DFTX

Did you know? Generalized anxiety disorder (GAD) affects ~26M adults in the U.S. New peer-reviewed research published in the Journal of Affective Disorders examines the clinical and economic burden of GAD—including the impact of being undiagnosed. Findings highlight lower quality of life and higher healthcare and productivity costs, with especially high burden among adults with GAD symptoms but no diagnosis. 🔗 Read the study: sciencedirect.com/science/articl… #GeneralizedAnxietyDisorder #MentalHealth #Psychiatry #BrainHealth

We’re pleased to announce the appointment of Roger Adsett to our Board of Directors. A seasoned biopharmaceutical leader, Roger brings deep experience building high-performing commercial organizations and guiding therapies from launch to meaningful market impact. 👉 Read the full announcement: ir.definiumtx.com/news-events/pr… $DFTX

Widely studied, then sidelined for decades, pharmaceutical LSD is now being re-examined for its potential to help patients living with mental health disorders. Learn more: bit.ly/49HJOME #DefiniumTherapeutics #Definium #BrainHealth #ReroutingMinds #Biotech

There is immense clinical potential in psychedelics. Learn more about Definium’s commitment to Rerouting Minds: bit.ly/49HJOME #DefiniumTherapeutics #Definium #BrainHealth #MentalHealthInnovation #Biotech #FutureOfPsychiatry #ReroutingMinds

On the heels of our exciting launch as Definium Therapeutics, we’re excited to have been at #ACNP2026! We presented four posters brimming with insights, such as treatment patterns for newly diagnosed GAD, gathered from real-world evidence: bit.ly/4pDmiWY #DefiniumTherapeutics

Definium Therapeutics lit up the Nasdaq tower today as we officially begin trading under our new name and ticker, $DFTX. This moment marks the next leap forward for our company and further showcases who we are, what we do, how we do it, and the precision and scientific rigor that sets us apart. Thank you to our teams, the mental health community, and supporters who helped make this moment possible. Learn more: definiumtx.com #DefiniumTherapeutics $DFTX #Nasdaq #CorporateMilestone #Biotech

Join Definium Therapeutics CEO Rob Barrow at the 44th Annual J.P. Morgan Healthcare Conference. 📅 Wednesday, January 14 ⏰ 2:15 PM PT / 5:15 PM ET Rob will discuss our exciting year ahead, anchored by our four phase 3 pivotal trials of DT120 ODT, redefining what treatment could mean for anxiety and depression. A live audio webcast will be available to investors and other interested parties and can be accessed here: lnkd.in/gb8hH5Ab #JPM2026 #HealthcareConference #DefiniumTherapeutics #BiotechLeadership #MentalHealth

BIG News. New Name. New Look. Same Mission: to forge a new era of psychiatry by  applying scientific rigor to psychedelics – developing accessible treatments that unlock healing at scale. Meet Definium Therapeutics. Guided by precision, fueled by our combined decades of experience in biotech, and powered by a radical idea: treatments for anxiety and depression should bring real relief for those who deserve more than better. Watch the reveal and learn more at DefiniumTX.com. #DefiniumTherapeutics #Biotech #BrainHealth #MentalHealth #MindMed

What defines our next chapter? Breakthrough Science. Bold Innovation. Transformational. Boundless. Precision. Rigor. More to come — stay tuned.

We believe progress shouldn’t inch ahead; it should leap forward. A bold new era is coming.